Cytokinetics Inc. Stock
€53.50
Your prediction
Cytokinetics Inc. Stock
Pros and Cons of Cytokinetics Inc. in the next few years
Pros
Cons
Performance of Cytokinetics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Cytokinetics Inc. | -4.460% | -0.926% | -9.322% | 13.830% | 17.841% | 23.272% | 220.359% |
| Ardelyx Inc. | -1.890% | 1.234% | -3.978% | 11.858% | -0.826% | 131.663% | -14.721% |
| Krystal Biotech | 0.850% | 4.672% | 13.930% | 39.043% | 41.327% | 190.676% | - |
| Champions Oncology Inc | 2.610% | 0.855% | 8.257% | 23.950% | 23.950% | 68.571% | -33.708% |
Comments
News
This Cytokinetics Director Sold 5,000 Shares in November. Is It Time to Dump the Biopharmaceutical Stock?
B. Lynne Parshall, Director at Cytokinetics, Incorporated (NASDAQ:CYTK), reported the sale of 5,000 shares in an open-market transaction valued at ~$323,650 on November 19, 2025; direct ownership
Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares
Foresite Capital Management IV, LLC disclosed a new stake in Cytokinetics (NASDAQ:CYTK), adding 458,295 shares valued at $25.19 million as of Sept. 30, 2025. The move was detailed in a quarterly
CYTK Earnings Jump 3,065%
Cytokinetics (NASDAQ:CYTK), a late-stage biopharmaceutical company focused on cardiovascular disease, reported earnings for Q2 FY2025 on August 7, 2025. The headline news was a dramatic


